Clinical trial
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
NCT00054834 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00054834 |
|---|---|
| Title | Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma |
| Official title | A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | hLL2 (epratuzumab) |
| Enrollment | 27 |
| Start date | Mar 1, 2003 |
| First posted | Feb 13, 2003 |
| Last update posted | Aug 16, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: